Wide Variation Found in Quality of Evidence Used By FDA For Approval of New Drugs

 

Wide Variation Found in Quality of Evidence Used By FDA For Approval of New Drugs

FOR RELEASE: 3 P.M. (CT) TUESDAY, JANUARY 21, 2014
Media Advisory: To contact corresponding author Joseph S. Ross, M.D., M.H.S., call Karen Peart at 203-432-1326 or email karen.peart@yale.edu. To contact editorial co-author Steven N. Goodman, M.D., M.H.S., Ph.D., call Ruthann Richter at 650-725-8047 or email richter1@stanford.edu

Chicago – Clinical trials used by the Food and Drug Administration (FDA) to approve new drugs between 2005 and 2012 vary widely in their characteristics, according to a study in the January 22/29 issue of JAMA.

“FDA review of new drug applications is guided by the Federal Food, Drug, and Cosmetic Act, which requires ‘adequate and well controlled investigations’ to determine efficacy,” according to background information in the article. “Many patients and physicians assume that the safety and effectiveness of newly approved therapeutic agents is well understood; however, the strength of the clinical trial evidence supporting approval decisions by the U.S. FDA has not been evaluated.”

Nicholas S. Downing, A.B., of the Yale University School of Medicine, New Haven, Conn., and colleagues evaluated the strength of clinical trial evidence supporting FDA approval decisions for new therapeutic agents by characterizing key features of pivotal efficacy trials (clinical trials that serve as the basis of FDA approval), such as trial size, design, duration, and end points.

The researchers used publicly available FDA documents to identify 188 novel therapeutic agents approved between 2005 and 2012 for 206 indications on the basis of 448 pivotal efficacy trials. The vast majority of pivotal trials were randomized (89 percent) and double-blinded (79.5 percent). More than half of the trials used a placebo for comparison (55 percent), and 32 percent used an active (such as another drug) comparator, and 13 percent had no comparator.

The median (midpoint) number of patients enrolled per indication among all pivotal trials was 760. Among 201 indications, 74 (37 percent) were approved on the basis of a single trial, 77 (38 percent) on 2, and 50 (25 percent) on 3 or more. Trials using surrogate end points as their primary outcome formed the exclusive basis of approval for 91 indications (45 percent).

At least 1 pivotal trial with a duration of 6 months or greater supported the approval of 68 indications (34 percent). Trial features differed by therapeutic and indication characteristics, such as therapeutic area, expected length of treatment, orphan status (drug used to treat rare medical condition), and accelerated approval.

“The variation in the [amount and type] of clinical trial evidence used by the FDA to assess the efficacy of novel therapeutic agents highlights the agency's flexible standards for approval,” the authors write. “Such regulatory flexibility allows for a customized approach to approval, including the ability to rapidly approve potentially effective therapies for life-threatening diseases, such as certain cancers, or those diseases for which there is no existing effective treatment, such as orphan diseases. These approvals can be made without requiring costly and time-consuming randomized, double-blinded, controlled trials, although these trials are regarded as the gold standard for evaluation.”

The researchers note that understanding the clinical trial evidence underlying newly approved therapeutic agents has important implications for patients and physicians. “When medications become available on the market, decisions must be made about their use, likely informed by how well safety and effectiveness are understood. Comparative effectiveness information, which is not required as part of FDA approval and involves comparison of an intervention with an active control, was available for less than half of indications, consistent with prior research, but leaving uncertainty about the benefits and safety of these medications when compared with other available therapeutic agents.”

The authors write that the wide variation in clinical trial evidence “has the potential to inform current FDA regulatory approval standards and postmarket surveillance initiatives.”
(doi:10.1001/jama.2013.282034)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: Opening the FDA Black Box

In an accompanying editorial, Steven N. Goodman, M.D., M.H.S., Ph.D., of Stanford University, Stanford, Calif., and Rita F. Redberg, M.D., M.Sc., of the University of California, San Francisco, and Editor, JAMA Internal Medicine, comment on the three studies in this issue of JAMA that examine the FDA approval process.

“Although these reports represent important steps in improving understanding of FDA decision making, further commitment to and progress toward ensuring transparency, including reducing report redactions, is needed to help the scientific community and other interested parties answer the questions these studies raise, thereby helping the FDA in its mission to find the right balance between allowing innovation and protecting the public's health.”
(doi:10.1001/jama.2013.283946)

Editor’s Note: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Redberg reported being a member of the U.S. Food and Drug Administration Circulatory System Devices Panel and a member of the California Technology Assessment Forum. No other conflicts of interest were reported.

# # #


Related Documents...

3918 VIDEO FINAL.doc : Filesize 147Kb
Video Script in DOC FormatDownload
3918 VIDEO FINAL.pdf : Filesize 94Kb
Video Script in PDF FormatDownload
3918 RADIO FINAL.doc : Filesize 61Kb
Radio Script in DOC FormatDownload
3918 RADIO FINAL.pdf : Filesize 101Kb
Radio Script in PDF FormatDownload


ON THE WEB...

Social Networks...

Facebook Myspace Twitter
LinkedIn Ning Hi5
Bebo Wordpress Blogger
Squarespace Tripod Typepad
CONTACT INFORMATION
Media Contact:

JAMA Media Relations
The JAMA Network
phone: 312.464.5262
email: mediarelations@jamanetwork.org

Technical Contact:

Rob Dalton
phone: 972.733.1595
email: rdalton@vnr1.com

Satellite Coordinates:

Satellite Feed Every Tuesday
9:00 - 9:15am (ET)
2:00 - 2:15pm (ET)
 
Galaxy 19
Transponder 12 C band, lower
18 mhz HD
Downlink: 3931 Horizontal
Symbol rate 12.8 FEC 3/4 QPSK
Trouble #: (312) 676-9855
 
AVAILABLE ON PATHFIRE in VNF Provider A
EACH TUESDAY AT 9 a.m. (ET)
Look for the JAMA Report Tab

MEDIA
Primary Video...


Primary JAMA Video | Length: 1:44Download SD Video
Download HD Video
Show Embed Link


Mobile Video...

Primary JAMA Video
Time: 1:44

Download for 3G
Primary JAMA Video
Time: 1:44

Download for iPhone
Related Broadcast Video...

Joseph S. Ross M.D. M.H.S. - Yale University School of Medicine
Time: :07

Download SD Video
Download HD Video
Nicholas S. Downing A.B. - Yale University School of Medicine
Time: :11

Download SD Video
Download HD Video
B-Roll: Looking at computer
Time: :10

Download SD Video
Download HD Video
B-Roll: Lab
Time: :10

Download SD Video
Download HD Video
Related Broadcast Audio...

Full Radio News Release TRT :60

Download MP3 Audio
Download WAV Audio
Related Images...

JAMA Logo

JAMA Cover